Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MED12 mutations in uterine leiomyomas: prediction of volume reduction by gonadotropin-releasing hormone agonists.

American journal of obstetrics and gynecology - 1 Feb 2023

Nagai Koichi, Asano Ryoko, Sekiguchi Futoshi, Asai-Sato Mikiko, Miyagi Yohei, Miyagi Etsuko

Abstract excerpt

BACKGROUND: Gonadotropin-releasing hormone agonists are used to treat premenopausal uterine leiomyomas; however, leiomyoma volume reduction is not always achieved. The reduction rate after this treatment varies for each leiomyoma, even in the same patient. Therefore, an effective method for predicting uterine leiomyoma volume reduction is required to reduce the adverse hypoestrogenic effects and drug-related...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Erythropoietin
Share to Gonadotropin-Releasing Hormone

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leiomyoma

Share to Mediator Complex

Share to Mutation

Share to Uterine Neoplasms

Source

Identifiers

PMID: 36150519
DOI: 10.1016/j.ajog.2022.09.024

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MED12 mutations in uterine leiomyomas: prediction of volume reduction by gonadotropin-releasing hormone agonists.PMID 36150519Read ↗

Frequency of MED12 Mutation in Relation to Tumor and Patient's Clinical Characteristics: a Meta-analysis.Semantic proximity Read ↗

Clinical decision making regarding leiomyomata: what we need in the next millenium.Semantic proximity Read ↗

Rare Diffuse Uterine Leiomyomatosis: Clinical Features and Outcomes in Nine Cases with Literature ReviewSemantic proximity Read ↗

Analysis of MED-12 mutations in uterine leiomyomas of Nigerian women.Semantic proximity Read ↗

The study of MED12 gene mutations in uterine leiomyomas from Iranian patients.Semantic proximity Read ↗

Clinical and Pathological Profiles and Recurrence Risk Factors of Uterine Leiomyoma Variants：A Retrospective Cohort StudySemantic proximity Read ↗

Quality of life after myomectomy according to the surgical approach and MED12 mutation status.Semantic proximity Read ↗

Novel Approaches to Possible Targeted Therapies and Prophylaxis of the Uterine FibroidSemantic proximity Read ↗

Missense mutations in exon 2 of the MED12 gene are involved in IGF-2 overexpression in uterine leiomyomaSemantic proximity Read ↗

Establishment of Noninvasive Prediction Models for the Diagnosis of Uterine Leiomyoma Subtypes.Semantic proximity Read ↗

The Role of MicroRNAs in Uterine Leiomyosarcoma Diagnosis and TreatmentSemantic proximity Read ↗

Uterine cellular leiomyomas are characterized by common HMGA2 aberrations, followed by chromosome 1p deletion and MED12 mutation: morphological, molecular, and immunohistochemical study of 52 cases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.